science

Matrixx Initiatives, Inc. v. Siracusano

Matrixx Initiatives, Inc. v. Siracusano is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Matrixx Initiatives, Inc. v. Siracusano rather than just read about it. In short: Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011), is a decision by the Supreme Court of the United States regarding whether a plaintiff can state a claim for securities fraud under §10(b) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. §78j(b), and Securities and Exchange Commission Rule 10b-5, 17 CFR §240.10b-5 (2010), based on a pharmaceutical company's failure to disclose reports of adver…

Key takeaways

Matrixx Initiatives, Inc. v. Siracusano belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Matrixx Initiatives, Inc. v. Siracusano to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Matrixx Initiatives, Inc. v. Siracusano from memory before moving on to harder problems.

Reference excerpt

Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011), is a decision by the Supreme Court of the United States regarding whether a plaintiff can state a claim for securities fraud under §10(b) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. §78j(b), and Securities and Exchange Commission Rule 10b-5, 17 CFR §240.10b-5 (2010), based on a pharmaceutical company's failure to disclose reports of adverse events associated with a product if the reports do not find statistically significant evidence that the adverse effects may be caused by the use of the product. In a 9–0 opinion delivered by Justice Sonia Sotomayor, the Court affirmed the Court of Appeals for the Ninth Circuit's ruling that the respondents, plaintiffs in a securities fraud class action against Matrixx Initiatives, Inc., and three Matrixx executives, had stated a claim under §10(b) and Rule 10b-5.

Parties Petitioners: Matrixx Initiatives, Inc., Carl Johnson, William Hemelt, and Timothy Clarot (collectively "Matrixx") Respondents: James Siracusano and NECA-IBEW Pension Fund, on behalf of themselves and all others similarly situated who purchased Matrixx securities between October 22, 2003, and February 6, 2004

Background Petitioner Matrixx Initiatives, Inc., is a pharmaceutical company that sells cold remedy products through its wholly owned subsidiary Zicam, LLC. One of Zicam's main products is Zicam Cold Remedy (Zicam), which is produced in the form of a nasal spray or gel containing the active ingredient zinc gluconate. On April 27, 2004, respondents brought a class action suit against petitioners, alleging that petitioners violated §10(b) of the Securities Exchange Act and SEC Rule 10b-5 by failing to disclose reports that Zicam could cause anosmia, or loss of the sense of smell. Petitioners filed a motion to dismiss respondents' complaint for failure to state a claim. The District Court for the District of Arizona granted the motion without prejudice, reasoning that the allegation of user complaints were neither material nor statistically significant, and that respondents failed to allege scienter. Respondents appealed to the Court of Appeals for the Ninth Circuit, which issued a decision on October 28, 2009, to reverse and remand the judgement of the District Court. On March 23, 2010, petitioners filed their petition for a writ of certiorari to the Ninth Circuit with the United States Supreme Court.

Decision On March 22, 2011, Justice Sotomayor delivered the 9–0 opinion that held "[r]espondents have stated a claim under §10(b) and Rule 10b-5", affirming 585 F.3d 1167.

Reactions to the decision An article by Carl Bialik appearing in The Wall Street Journal on April 2, 2011, reported:

In [the] opinion, the justices said companies can't only rely on statistical significance when deciding what they need to disclose to investors. Amen, say several statisticians who have long argued that the concept of statistical significance has unjustly overtaken other barometers used to determine which experimental results are valid and warrant public distribution. "Statistical significance doesn't tell you everything about the truth of the hypothesis you're exploring," says Steven Goodman, an epidemiologist and biostatistician at the Johns Hopkins Bloomberg School of Public Health.

Erik Olson, a partner at the Morrison & Foerster law firm in San Francisco which filed an amicus brief on behalf of BayBio, said that the court's ruling risks leaving companies without a clear guideline for deciding when they need to disclose adverse events. Olson, Stephen Thau, and Stefan Szpajda wrote a press release stating:

Life sciences companies and other public companies can learn at least two lessons from the decision. First and foremost, be careful what you say. As the Court emphasized, the securities laws focus on false or misleading speech. "[C]ompanies can control what they have to disclose under these provisions by controlling what they say to the market." (Slip Op. at 16). Rash or categorical comments are far more likely to form the basis for a lawsuit than measured, careful statements about the facts. Second, life sciences companies should consult carefully with lawyers regarding specific disclosures and policies and practices for disclosing adverse events.

References

External links Text of Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011) is available from: Internet Archive (docket files) Justia Oyez (oral argument audio) Supreme Court (slip opinion) (archived) Opinion Below "Matrixx Initiatives, Inc. v. Siracusano". SCOTUSblog. 2011. Retrieved April 16, 2011.

Worked examples

Example 1 — a first encounter with Matrixx Initiatives, Inc. v. Siracusano

Start with the simplest possible case. Write down what Matrixx Initiatives, Inc. v. Siracusano claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Matrixx Initiatives, Inc. v. Siracusano before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Matrixx Initiatives, Inc. v. Siracusano ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Matrixx Initiatives, Inc. v. Siracusano

In research: Matrixx Initiatives, Inc. v. Siracusano appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Matrixx Initiatives, Inc. v. Siracusano in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Matrixx Initiatives, Inc. v. Siracusano is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drug safety, International Brotherhood of Electrical Workers, United States Supreme Court cases, so understanding it makes those chapters shorter.
In everyday life: Look for Matrixx Initiatives, Inc. v. Siracusano outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Matrixx Initiatives, Inc. v. Siracusano” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Matrixx Initiatives, Inc. v. Siracusano in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Matrixx Initiatives, Inc. v. Siracusano means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Matrixx Initiatives, Inc. v. Siracusano out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Matrixx Initiatives, Inc. v. Siracusano in simple terms?

Why does Matrixx Initiatives, Inc. v. Siracusano matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Matrixx Initiatives, Inc. v. Siracusano?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Matrixx Initiatives, Inc. v. Siracusano.